Form 4: Ultragenyx Officer Sells Shares for Tax Obligations

Sentiment:

Insider Transaction Report


Ultragenyx Pharmaceutical Inc.'s SVP, Chief Accounting Officer, Theodore Alan Huizenga, disposed of shares to cover tax withholdings related to RSU vesting.

Summary

  • Theodore Alan Huizenga, SVP, Chief Accounting Officer of Ultragenyx Pharmaceutical Inc., reported transactions involving common stock.
  • On March 2, 2026, 148 shares were surrendered to the Issuer at a price of $23.39 per share to cover required tax withholdings due to the vesting of Restricted Stock Units (RSUs).
  • Additionally, 1,632 shares were sold on March 2, 2026, at a weighted average price of $22.80 per share, with individual transaction prices ranging from $22.54 to $23.11, also to satisfy tax withholdings from RSU vesting.
  • Following these transactions, Mr. Huizenga beneficially owns 48,670 shares of Ultragenyx common stock, which includes previously reported shares underlying RSUs subject to certain vesting conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The transactions are routine, non-discretionary sales for tax purposes related to RSU vesting and do not reflect a change in the insider's investment sentiment or the company's fundamentals.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions and do not typically reflect broader industry trends. These transactions are routine for executives receiving equity compensation.

Key Dates

DateDescription
03/02/2026Date of common stock transactions (surrender and sale for tax withholdings).
03/03/2026Date the Statement of Changes in Beneficial Ownership (Form 4) was signed and filed.

Recommendation

hold

This Form 4 filing details routine, non-discretionary transactions by an executive to cover tax liabilities associated with RSU vesting. Such transactions do not provide new fundamental information about Ultragenyx Pharmaceutical Inc. or signal a change in the executive's confidence in the company. Therefore, a seasoned investor would likely maintain their current position, as this filing does not warrant a change in investment thesis.

Keywords

Ultragenyx Pharmaceutical, RARE, Insider Trading, Form 4, RSU Vesting, Tax Withholding, Theodore Alan Huizenga

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.